Mycophenolate Mofetil: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation

Drugs

Volumn 51, Issue 2, 1996, Pages 278-298

  Fulton, Bret ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ACICLOVIR; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIBODY; ANTIGEN; AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; INOSINATE DEHYDROGENASE; METHYLPREDNISOLONE; MITOGENIC AGENT; NUCLEOTIDE;

ANIMAL; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; REVIEW; ANEMIA; ANTIBODY PRODUCTION; B LYMPHOCYTE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; ENZYME INHIBITION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; LYMPHOMA; NONHUMAN; NUCLEOTIDE METABOLISM; ORAL DRUG ADMINISTRATION; SEPSIS; SKIN CANCER; T LYMPHOCYTE; TREATMENT FAILURE; VIREMIA; VOMITING;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0030074991     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651020-00007     Document Type: Review

References (78)

1. Morris RE. Immunopharmacology of new xenobiotic immunosuppressive molecules. Semin Nephrol 1992 Jul; 12: 304-14
2. Goldsmith MF. Researchers follow varied molecular paths toward better control of organ rejection [news]. JAMA 1990 Mar 2; 263: 1184,1187
3. Sharma VK, Li B, Khanna A, et al. Which way for drug-mediated immunosuppression? Curr Opin Immunol 1994 Oct; 6: 784-90
4. Handschumacher RE. Immunosuppressive agents. In: Gilman AG, Rall TW, Nies AS, et al., editors. Goodman & Gilman's the pharmacological basis of therapeutics. 8th ed. v. 2. New York: McGraw-Hill, Inc, 1992: 1264-76
5. Young CJ, Sollinger HW. RS-61443: a new immunosuppressive agent. Transplant Proc 1994 Dec; 26: 3144-6
6. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993 Nov-Dec; 12: S275-86
7. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transpl 1993 Feb; 7 (Pt 2): 96-112
8. Lee H-J, Pawlak K, Nguyen BT, et al. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 1985 Nov; 45 (11 Pt 1): 5512-20
9. Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987; 7 (5): 165-77
10. Allison AC, Almquist SJ, Muller CD, et al. In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc 1991 Apr; 23 Suppl. 2: 10-4
11. Burlingham WJ, Grailer AP, Hullett DA, et al. Inhibition of both MLC and in vitro IgG memory response to tetanus toxoid by RS-61443. Transplantation 1991 Feb; 51: 545-7
12. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991 Feb; 33: 161-73
13. Grailer A, Nichols J, Hullett D, et al. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 11-2. Transplant Proc 1991 Feb; 23: 314-5
14. Weaver JL, Pine PS, Aszalos A. Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. Immunopharmacol Immunotoxicol 1991; 13: 563-76
15. Zeevi A, Woan M, Yao GZ, et al. Comparative in vitro studies on the immunosuppressive activities of myeophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. Transplant Proc 1991 Dec; 23: 2928-30
16. Sokoloski JA, Sartorelli AC. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and myeophenolic acid, on glycoprotein metabolism. Mol Pharmacol 1985 Dec; 28: 567-73
17. Laurent AF, Dumont S, Poindron P, et al. Inhibition of mannosylation on human monocyte surface glycoprotein could explain some of the anti-inflammatory effects of mycophenolate mofetil [abstract]. Clin Exp Rheumatol 1994 Nov-Dec; 12 Suppl. 11: 110
18. + human lymphocytes. Transplant Proc 1991 Dec; 23: 2939-40
19. Kiguchi K, Collart FR, Henning-Chubb C, et al. Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin. Exp Cell Res 1990 Mar; 187: 47-53
20. Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res 1989 Oct 15; 49: 5555-60
21. Dayton JS, Turka LA, Thompson CB, et al. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on lymphocyte-T proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992 Apr; 41: 671-6
22. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993 Apr; 14: 353-80
23. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991 Feb; 33: 175-83
24. Figueroa J, Fuad SA, Kunjummen BD. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443). Its potential use in discordant xenografting. Transplantation 1993 Jun; 55: 1371-4
25. Soares MP, Latinne D, Elsen M, et al. In vivo depletion of xenoreactive natural antibodies with an anti-μ monoclonal antibody. Transplantation 1993 Dec; 56: 1427-33
26. Kimball JA, Pescovitz MD, Book BK, et al. Mycophenolate mofetil reduces human IGG anti-ATGAM antibody formation [abstract no. 183]. 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research; 1995 May 7-11; San Diego
27. Morris RE, Wang J. Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant Proc 1991 Feb; 23: 493-6
28. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990 Aug; 22: 1659-62
29. Kawamura T, Hullett DA, Suzuki Y, et al. Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy. Transplantation 1993 Apr; 55: 691-5
30. Tanabe M, Todo S, Murase N, et al. Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplantation 1994 Jul 15; 58: 23-7
31. Knechtle SJ, Wang J, Burlingham WJ, et al. The influence of RS-61443 on antibody-mediated rejection. Transplantation 1992 Mar; 53: 699-701
32. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991 Apr; 23 Suppl. 2: 19-25
33. Hullett DA, Kawamura T, Fujino Y, et al. Prolongation of allograft and xenograft survival with mycophenolate mofetil (RS-61443) and brequinar sodium (DUP-785). Transplant Proc 1993 Feb; 25 (Pt 1): 700-1
34. Wang J, Morris RE. Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival. Transplant Proc 1991 Feb; 23 (1 Pt 1): 699-702
35. Murase N, Starzl TE, Demetris AJ, et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 1993 Apr; 55: 701-7 (discussion 707-8)
36. Ohair DP, McManus RP, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994 Nov; 58: 1311-5
37. Yatscoff RW, Wang S, Keenan R. Efficacy of rapamycin. RS-61443, and cyclophosphamide in the prolongation of survival of discordant pig-to-rabbit cardiac xenografts. Transplant Proc 1994 Jun; 26: 1271-3
38. Bechstein WO, Schilling M, Steele DM, et al. RS-61443/ cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993 Feb; 25 (Pt 1): 702-3
39. Coulombe M, Hao L, Calcinaro F, et al. Tolerance induction in adult animals: comparison of RS-61433 and anti-CD4 treatment. Transplant Proc 1991 Apr; 23 Suppl. 2: 31-2
40. Hao L, Lafferty KJ, Allison AC, et al. RS-61443 allows islet allografting and specific tolerance induction in adult mice. Transplant Proc 1990 Apr; 22: 876-9
41. Hao L, Calcinaro F, Lafferty KJ, et al. Tolerance induction in adult mice: cyclosporine inhibits RS-61443-induced tolerance. Transplant Proc 1991 Feb; 23 (1 Pt 1): 733-4
42. Daloze P, Chen H, Qi S, et al. Prolongation of pancreas allograft survival by RS 61443 in the rat [abstract]. International Congress on New Immunosuppressive Drugs; 1995 Aug 27; Montreal, Canada
43. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991 Jan; 51; 27-31
44. Azuma H, Binder J, Heemann U, et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995 Feb 27; 59: 460-6
45. Platz KP, Bechstein WO, Eckhoff DE, et al. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991 Oct; 110: 736-41
46. Hao L, Calcinaro F, Gill RG, et al. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992 Mar; 53: 590-5
47. Hoffmann-La Roche Inc. Mycophenolate mofetil prescribing information. Nutley (NJ): 1995
48. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992 Feb; 53: 428-32
49. Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Ther Drug Monit 1994 Dec; 16: 602-7
50. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990 Feb; 7: 161-6
51. Shah J, Bullingham R, Rice P, et al. Pharmacokinetics of oral mycophenolate mofetil and metabolites in renally impaired patients [abstract]. Clin Pharmacol Ther 1995 Feb; 57: 149
52. Shah J, Juan D, Bullingham R, et al. A single dose drug interaction study of mycophenolate mofetil and acyclovir in normal subjects [abstract]. J Clin Pharmacol 1994 Oct; 34: 1029
53. Wolfe EJ, Mathur VS, Tomlanovich S, et al. Pharmacokinetic drug interaction study of mycophenolate mofetil and IV ganciclovir in renal transplant patients [abstract]. Clin Pharmacol Ther 1995 Feb; 57: 148
54. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years - early events affecting transplant success. Transplantation 1992 Jan; 53 (1): 59-64
55. Schweitzer EJ, Mutas AJ, Gillingham KJ, et al. Causes of renal allograft loss. Ann Surg 1991; 214: 679
56. Halloran PF. New trends in immunosuppression for renal transplantation. Curr Opin Nephrol Hypertension 1994 Nov; 3: 575-7
57. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993 May; 217: 476-84
58. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995 Feb; 27: 1421-4
59. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 May 27; 345: 1321-5
60. Häyry P for the IMMRTSG. Mycophenolate mofetil (MMF) for acute rejection of cadaveric renal transplants: results of a randomized, double-blind multicenter study [abstract no. 179]. 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research; 1995 May 7-11, San Diego
61. Sollinger for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995 Aug 15; 60 (3): 225-32
62. Salaman JR, Griffin PJA, Johnson RWG, et al. Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy. Transplant Proc 1993 Feb; 25 (Pt 1): 695-6
63. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993 Apr; 55 (4): 752-7
64. Gulanikar AC, MacDonald AS, Sungurtekin U, et al. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992 Feb; 53 (2): 323-8
65. van Saase JLCM, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995 May 15; 59 (9): 1280-5
66. Laskow DA, Deierhoi MH, Hudson SL, et al. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). Transplantation 1994 Feb 27; 57: 640-3
67. Neyland JF, Deierhoi MH, The US Mycophenolate Mofetil Study Group. Dose-dependent prevention of acute renal transplant rejection in African-Americans receiving mycophenolate mofetil (MMF) [abstract no. 182]. 105th Annual Meeting of the American Pediatric Society and the 64th Annual meeting of the Society for Pediatric Research; 1995 May 7-11; San Diego
68. Ettenger RB, Mentser MI, Potter DE, et al. Mycophenolate mofetil in pediatric renal transplantation: a report of the Pediatric Mycophenolate Study Group [abstract no. 2151]. Pediatr Res 1995 Apr; 37 (Pt 2): 361A
69. Khalili R, Wilkinson AH, Danovitch G. Single institution results in salvage treatment of OKT3-treated kidney transplant rejection with mycophenylate mofetil [abstract]. J Urol 1995 Apr; 153 Suppl.: 399
70. Rosenthal JT, US Renal Transplant Refractory Rejection Mycophenolate Mofetil Study Group. Mycophenolate mofetil is effective treatment for refractory acute rejection in renal allograft recipients [abstract no. 180]. 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research; 1995 May 7-11; San Diego
71. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil) - a multicenter study for refractory kidney transplant rejection. Ann Surg 1992 Oct; 216: 513-9
72. Gonwa TA, The US Renal Transplant Mycophenolate Mofetil Study Group. Safety of mycophenolate mofetil (MMF) vs azathioprine (AZA) in primary cadaveric renal transplant (cad TX) [abstract no. 184]. 105th Annual Meeting of the American Pediatric Society and the 64th Annual Meeting of the Society for Pediatric Research; 1995 May 7-11; San Diego
73. Ho M, Dummer JS. Risk factors and approaches to infections in transplant recipients. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practices of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 2284-91
74. Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transpl 1994; 8: 388-95
75. Barry JM. Immunosuppressive drugs in renal transplantation: a review of the regimens. Drugs 1992 Apr; 44 (4): 554-66
76. Salomon DR. The use of immunosuppressive drugs in kidney transplantation. Pharmacotherapy 1991; 11 (6): 153S-64S
77. Stiller CR, Opelz G. Should cyclosporine be continued indefinitely? Transplant Proc 1991 Feb; 23 (1): 36-40
78. Krensky AM, Clayberger C. Prospects for induction of tolerance in renal transplantation. Pediatr Nephrol 1994; 8: 772-9